cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.7000451.v1
title: Supplementary Material for: Prognostic Impact of miR-200 Family Members in Plasma and Exosomes from Tumor-Draining versus Peripheral Veins of Colon Cancer Patients

description: <b><i>Objective:</i></b> To evaluate the prognostic potential of expression levels of miR-200 family members (miR-200a, miR-200b, miR-200c, miR-429, miR-141) in plasma and exosomes from the tumor-draining vein (mesenteric vein [MV]) and peripheral vein (PV) of colon cancer (CC) patients. <b><i>Methods:</i></b> We analyzed the expression of miR-200 family members in matched samples of MV and PV plasma from 50 resected patients with CC and correlated our findings with overall survival (OS). We also examined the content of these microRNAs in MV and PV exosomes. <b><i>Results:</i></b> Expression levels were higher in MV than in PV (miR-200a, <i>p</i> &lt; 0.001; miR-200b, <i>p</i> &lt; 0.001; miR-429, <i>p</i> = 0.01; miR-200c, <i>p</i> = 0.05; miR-141, <i>p</i> = 0.05). Low levels of both miR-200c and miR-141 in MV plasma were associated with longer OS (<i>p</i> = 0.02). This association was maintained for the MV exosome cargo of miR-200c and miR-141 (<i>p</i> = 0.02). <b><i>Conclusion:</i></b> Our findings provide the first indication that expression levels of miR-200c and miR-141 in MV plasma can identify CC patients with poor prognosis. In addition, our results lend further support to the premise that tumor-draining veins constitute a better source of biomarkers than do PVs.
DOI: 10.7284/104567
title: Multiplexed data collected during research cruise HRS110705BC using a Delaware SMS instrument system onboard the platform RV Hugh R. Sharp
DOI: 10.6084/m9.figshare.7000361
title: testCode

description: Test
DOI: 10.6084/m9.figshare.7000355
title: Lumpfish Genotype Data.xlsx

description: Microsatellite data lumpfish
DOI: 10.6084/m9.figshare.7000331
title: Impact of Palliative Chemotherapy and Best Supportive Care on Overall Survival and Length of Hospitalization in Patients with Incurable Cancer: A 4-Year Single Institution Experience in Japan raw data

description: A total of 129 patients were enrolled in this study.This table shows that sex, age, disease, treatment choice, outcome, overall survival and length of hospitalizaon.
DOI: 10.6084/m9.figshare.7000355.v2
title: Lumpfish Genotype Data.xlsx

description: Microsatellite data lumpfish
DOI: 10.6084/m9.figshare.7000331.v1
title: Impact of Palliative Chemotherapy and Best Supportive Care on Overall Survival and Length of Hospitalization in Patients with Incurable Cancer: A 4-Year Single Institution Experience in Japan raw data

description: A total of 129 patients were enrolled in this study.This table shows that sex, age, disease, treatment choice, outcome, overall survival and length of hospitalizaon.
DOI: 10.6084/m9.figshare.7000355.v1
title: Lumpfish Genotype Data.xlsx

description: Microsatellite data lumpfish
DOI: 10.6084/m9.figshare.7000298
title: Supplementary Material for: Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

description: <b><i>Background:</i></b> In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. <b><i>Methods:</i></b> In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to those of the phase III study. The primary endpoint was investigator-assessed PFS per Response Evaluation Criteria in Solid Tumours v1.0 (RECIST). Other endpoints included PFS per Choi criteria, overall survival (OS), objective response rate (ORR), and adverse events (AEs). <b><i>Results:</i></b> Sixty-one treatment-naive and 45 previously treated patients received sunitinib. By March 19, 2016, 82 (77%) patients had discontinued treatment, mainly due to disease progression. Median treatment duration was 11.7 months. Investigator-assessed median PFS per RECIST (95% confidence interval [CI]) was 13.2 months (10.9–16.7): 13.2 (7.4–16.8) and 13.0 (9.2–20.4) in treatment-naive and previously treated patients, respectively. ORR (95% CI) per RECIST was 24.5% (16.7–33.8) in the total population: 21.3% (11.9–33.7) in treatment-naive and 28.9% (16.4–44.3) in previously treated patients. Median OS, although not yet mature, was 37.8 months (95% CI, 33.0–not estimable). The most common treatment-related AEs were neutropenia (53.8%), diarrhoea (46.2%), and leukopenia (43.4%). <b><i>Conclusions:</i></b> This phase IV trial confirms sunitinib as an efficacious and safe treatment option in patients with advanced/metastatic, well-differentiated, unresectable panNETs, and supports the phase III study outcomes. AEs were consistent with the known safety profile of sunitinib.
DOI: 10.6084/m9.figshare.7000319
title: Supplementary Material for: The Lymph Node Ratio Optimizes Staging in Patients with Small Intestinal Neuroendocrine Tumors

description: <b><i>Background:</i></b> The effectiveness of the current Tumor, Lymph node, Metastases (TNM) staging system in small intestinal neuroendocrine tumors (SiNETs) is unsatisfactory. Current N classification only distinguishes between node-negative and node-positive status. We aim to refine the N classification for updated TNM stage. <b><i>Methods:</i></b> During the period from 1988 to 2012, patients with non-metastatic ­SiNETs were enrolled in the Surveillance, Epidemiology, and End Results database. Using the X-tile program, we calculated an optimal cutoff value for lymph node ratio (LNR) and proposed a novel Nr category. Survival outcomes were estimated using the Kaplan-Meier method and Cox regression model. Adjusted hazard ratio (HR) and cluster analysis were performed to differentiate TNrM stages. <b><i>Results:</i></b> Patients with existing TNM stage I and II had equivalent survival prognosis (<i>p</i> = 0.214). Current N classification was not a significant predictor of patient survival (<i>p</i> = 0.372). Multivariate analyses identified the revised Nr classification, based on LNR of 0.6 optimal cutoff value, as an independent prognostic factor (<i>p</i> = 0.020). By incorporating the Nr classification, a revised TNrM, which categorized patients into 3 new stages was proposed: stage I (T1–2Nr0–1), stage II (T3Nr0–1), and stage III (TxNr2 or T4Nrx). TNrM stage had better stratification according to the survival outcome (primary cohort: stage I: reference, II: HR 3.852, 95% CI 1.731–8.575; III: HR 7.169, 95% CI 3.220–15.963, <i>p</i> &lt; 0.001; validation cohort: stage I: reference, II: HR 2.034; III: HR 3.815; <i>p</i> &lt; 0.001). <b><i>Conclusions:</i></b> The Nr classification more accurately stratifies SiNET patients than current N classification. The new TNrM staging system could improve the ability to predict survival outcome of SiNET patients.
DOI: 10.6084/m9.figshare.7000298.v1
title: Supplementary Material for: Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours

description: <b><i>Background:</i></b> In a phase III study, sunitinib led to a significant increase in progression-free survival (PFS) versus placebo in patients with pancreatic neuroendocrine tumours (panNETs). This study was a post-marketing commitment to support the phase III data. <b><i>Methods:</i></b> In this ongoing, open-label, phase IV trial (NCT01525550), patients with progressive, advanced unresectable/metastatic, well-differentiated panNETs received continuous sunitinib 37.5 mg once daily. Eligibility criteria were similar to those of the phase III study. The primary endpoint was investigator-assessed PFS per Response Evaluation Criteria in Solid Tumours v1.0 (RECIST). Other endpoints included PFS per Choi criteria, overall survival (OS), objective response rate (ORR), and adverse events (AEs). <b><i>Results:</i></b> Sixty-one treatment-naive and 45 previously treated patients received sunitinib. By March 19, 2016, 82 (77%) patients had discontinued treatment, mainly due to disease progression. Median treatment duration was 11.7 months. Investigator-assessed median PFS per RECIST (95% confidence interval [CI]) was 13.2 months (10.9–16.7): 13.2 (7.4–16.8) and 13.0 (9.2–20.4) in treatment-naive and previously treated patients, respectively. ORR (95% CI) per RECIST was 24.5% (16.7–33.8) in the total population: 21.3% (11.9–33.7) in treatment-naive and 28.9% (16.4–44.3) in previously treated patients. Median OS, although not yet mature, was 37.8 months (95% CI, 33.0–not estimable). The most common treatment-related AEs were neutropenia (53.8%), diarrhoea (46.2%), and leukopenia (43.4%). <b><i>Conclusions:</i></b> This phase IV trial confirms sunitinib as an efficacious and safe treatment option in patients with advanced/metastatic, well-differentiated, unresectable panNETs, and supports the phase III study outcomes. AEs were consistent with the known safety profile of sunitinib.
DOI: 10.6084/m9.figshare.7000319.v1
title: Supplementary Material for: The Lymph Node Ratio Optimizes Staging in Patients with Small Intestinal Neuroendocrine Tumors

description: <b><i>Background:</i></b> The effectiveness of the current Tumor, Lymph node, Metastases (TNM) staging system in small intestinal neuroendocrine tumors (SiNETs) is unsatisfactory. Current N classification only distinguishes between node-negative and node-positive status. We aim to refine the N classification for updated TNM stage. <b><i>Methods:</i></b> During the period from 1988 to 2012, patients with non-metastatic ­SiNETs were enrolled in the Surveillance, Epidemiology, and End Results database. Using the X-tile program, we calculated an optimal cutoff value for lymph node ratio (LNR) and proposed a novel Nr category. Survival outcomes were estimated using the Kaplan-Meier method and Cox regression model. Adjusted hazard ratio (HR) and cluster analysis were performed to differentiate TNrM stages. <b><i>Results:</i></b> Patients with existing TNM stage I and II had equivalent survival prognosis (<i>p</i> = 0.214). Current N classification was not a significant predictor of patient survival (<i>p</i> = 0.372). Multivariate analyses identified the revised Nr classification, based on LNR of 0.6 optimal cutoff value, as an independent prognostic factor (<i>p</i> = 0.020). By incorporating the Nr classification, a revised TNrM, which categorized patients into 3 new stages was proposed: stage I (T1–2Nr0–1), stage II (T3Nr0–1), and stage III (TxNr2 or T4Nrx). TNrM stage had better stratification according to the survival outcome (primary cohort: stage I: reference, II: HR 3.852, 95% CI 1.731–8.575; III: HR 7.169, 95% CI 3.220–15.963, <i>p</i> &lt; 0.001; validation cohort: stage I: reference, II: HR 2.034; III: HR 3.815; <i>p</i> &lt; 0.001). <b><i>Conclusions:</i></b> The Nr classification more accurately stratifies SiNET patients than current N classification. The new TNrM staging system could improve the ability to predict survival outcome of SiNET patients.
DOI: 10.6084/m9.figshare.7000271
title: Allele calling data

description: This is the SSR genotypic data of the isolates published in <b>Population structure of <i>Colletotrichum tanaceti </i>in Australian pyrethrum reveals high evolutionary potential</b><br>
DOI: 10.6084/m9.figshare.7000271.v2
title: Allele calling data

description: This is the SSR genotypic data of the isolates published in <b>Population structure of <i>Colletotrichum tanaceti </i>in Australian pyrethrum reveals high evolutionary potential</b><br>
DOI: 10.6084/m9.figshare.7000271.v1
title: Allele calling data

description: This is the SSR genotypic data of the isolates published in <b>Population structure of <i>Colletotrichum tanaceti </i>in Australian pyrethrum reveals high evolutionary potential</b><br>
DOI: 10.6084/m9.figshare.6999896
title: Additional file 2 of The capacity-building and science-enabling activities of the IUGONET for the solar-terrestrial research community

description: IUGONET_Instrument.KMZ. A KMZ file for Google Earth to show the location and parameters of IUGONET instruments and each link to the metadata database.
DOI: 10.6084/m9.figshare.6999896.v1
title: Additional file 2 of The capacity-building and science-enabling activities of the IUGONET for the solar-terrestrial research community

description: IUGONET_Instrument.KMZ. A KMZ file for Google Earth to show the location and parameters of IUGONET instruments and each link to the metadata database.
DOI: 10.6084/m9.figshare.6999881
title: Additional file 1 of The capacity-building and science-enabling activities of the IUGONET for the solar-terrestrial research community

description: IUGONET_Observatory.KMZ. A KMZ file for Google Earth to show the locations of IUGONET observatories and each link to the metadata database.
DOI: 10.6084/m9.figshare.6999881.v1
title: Additional file 1 of The capacity-building and science-enabling activities of the IUGONET for the solar-terrestrial research community

description: IUGONET_Observatory.KMZ. A KMZ file for Google Earth to show the locations of IUGONET observatories and each link to the metadata database.
DOI: 10.7284/107877
title: Multiplexed data collected during research cruise HRS120905ZJ using a Delaware SMS instrument system onboard the platform RV Hugh R. Sharp
DOI: 10.6084/m9.figshare.6999809
title: Additional file 3: of The genome of the biting midge Culicoides sonorensis and gene expression analyses of vector competence for bluetongue virus

description: Supplementary Alignments. Zip file containing the gst-1 and ski2 CDS and protein sequences, the protein alignment obtained using T-Coffee as described in the Additional file 1: Supplementary Methods, and the protein alignment after removing variable positions (with a T-Coffee value
DOI: 10.6084/m9.figshare.6999809.v1
title: Additional file 3: of The genome of the biting midge Culicoides sonorensis and gene expression analyses of vector competence for bluetongue virus

description: Supplementary Alignments. Zip file containing the gst-1 and ski2 CDS and protein sequences, the protein alignment obtained using T-Coffee as described in the Additional file 1: Supplementary Methods, and the protein alignment after removing variable positions (with a T-Coffee value
DOI: 10.6084/m9.figshare.6999788
title: Additional file 1: of Influence of sample collection tube method, anticoagulant-containing plasma versus serum, on influenza virus hemagglutination inhibition titer and microneutralization titer serological assays

description: HAI and MN Titer Values. HAI and MN titer values for all influenza types for the thirty matched samples and for the six collection tube methods. (XLSX 27 kb)
DOI: 10.6084/m9.figshare.6999788.v1
title: Additional file 1: of Influence of sample collection tube method, anticoagulant-containing plasma versus serum, on influenza virus hemagglutination inhibition titer and microneutralization titer serological assays

description: HAI and MN Titer Values. HAI and MN titer values for all influenza types for the thirty matched samples and for the six collection tube methods. (XLSX 27 kb)
DOI: 10.6084/m9.figshare.6999761
title: Additional file 9: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S9. Upregulated bioprocesses resulting from different overlaps of poor diet comparisons. Upregulated bioprocesses, in healthy bees, generated by carbohydrates-only feeding in the overlaps of pollen and Bee-Pro (C &gt; P/ C &gt; B), Bee-Pro and MegaBee (C &gt; B/ C &gt; M), and the triple overlap of pollen, Bee-Pro and MegaBee (C &gt; P/ C &gt; B/ C &gt; M) are listed; also listed are the same comparisons in presence of Nosema, respectively, CN &gt; PN/ CN &gt; BN, CN &gt; BN/ CN &gt; MN and CN &gt; PN/ CN &gt; BN/ CN &gt; MN; the comparison CN &gt; PN/ CN &gt; MN indicates overlap of upregulation by poor diet when compared to pollen and MegaBee in infected bees. The upregulated bioprocesses generated by carbohydrates-only when compared to pollen in healthy and Nosema-infected bees (C &gt; P/ CN &gt; PN) are also indicated. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.6999761.v1
title: Additional file 9: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S9. Upregulated bioprocesses resulting from different overlaps of poor diet comparisons. Upregulated bioprocesses, in healthy bees, generated by carbohydrates-only feeding in the overlaps of pollen and Bee-Pro (C &gt; P/ C &gt; B), Bee-Pro and MegaBee (C &gt; B/ C &gt; M), and the triple overlap of pollen, Bee-Pro and MegaBee (C &gt; P/ C &gt; B/ C &gt; M) are listed; also listed are the same comparisons in presence of Nosema, respectively, CN &gt; PN/ CN &gt; BN, CN &gt; BN/ CN &gt; MN and CN &gt; PN/ CN &gt; BN/ CN &gt; MN; the comparison CN &gt; PN/ CN &gt; MN indicates overlap of upregulation by poor diet when compared to pollen and MegaBee in infected bees. The upregulated bioprocesses generated by carbohydrates-only when compared to pollen in healthy and Nosema-infected bees (C &gt; P/ CN &gt; PN) are also indicated. (XLSX 12 kb)
DOI: 10.6084/m9.figshare.6999752
title: Additional file 8: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S8. a) Gene overlap of pollen and Bee-Pro feeding (P vs. C/ B vs. C), pollen and MegaBee feeding (P vs. C/ M vs. C) and Bee-Pro and MegaBee feeding (B vs. C/ M vs. C) in healthy bees. b) Respectively, P vs. C, B vs. C and M vs. C are healthy bees fed pollen (P), Bee-Pro (B) and MegaBee (B) compared to carbohydrates only (C); respectively, PN vs. CN, BN vs. CN and MN vs. CN are the same diet treatments in Nosema-infected. c) Gene overlaps of PN vs. CN/ BN vs. CN, PN vs. CN/ MN vs. CN and BN vs. CN/ MN vs. CN are, respectively, the same diet comparisons in presence of Nosema. RF is the representation factor indicating fold enrichment for the overlap, and p-value is the overlap statistical likelihood based on a hypergeometric distribution. (XLSX 10Â kb)
DOI: 10.6084/m9.figshare.6999752.v1
title: Additional file 8: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S8. a) Gene overlap of pollen and Bee-Pro feeding (P vs. C/ B vs. C), pollen and MegaBee feeding (P vs. C/ M vs. C) and Bee-Pro and MegaBee feeding (B vs. C/ M vs. C) in healthy bees. b) Respectively, P vs. C, B vs. C and M vs. C are healthy bees fed pollen (P), Bee-Pro (B) and MegaBee (B) compared to carbohydrates only (C); respectively, PN vs. CN, BN vs. CN and MN vs. CN are the same diet treatments in Nosema-infected. c) Gene overlaps of PN vs. CN/ BN vs. CN, PN vs. CN/ MN vs. CN and BN vs. CN/ MN vs. CN are, respectively, the same diet comparisons in presence of Nosema. RF is the representation factor indicating fold enrichment for the overlap, and p-value is the overlap statistical likelihood based on a hypergeometric distribution. (XLSX 10Â kb)
DOI: 10.6084/m9.figshare.6999740
title: Additional file 7: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S7. Bioprocesses upregulated under poor diet, overlapping with the study by Ament et al. (2011). Upregulation in healthy bees (no-nosema) under carbohydrates-only feeding is represented compared to pollen (C &gt; P), and in presence of Nosema compared to MegaBee (MN &gt; CN) and pollen (PN &gt; CN). Overlapping bioprocesses with the study by Ament et al. (2011) are listed; upregulated treatments in the latter study are forager vs. nurse vs. (F &gt; N), poor diet vs. rich (Pr &gt; R), vitellogenin RNAi vs. vitellogenin wild type (Vg(−) &gt; Vg). All listed bioprocesses are upregulated in this study (+); the non-concordant bioprocesses in direction of regulation in Ament et al. are indicated by the sign minus (−). (XLSX 11 kb)
DOI: 10.6084/m9.figshare.6999740.v1
title: Additional file 7: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S7. Bioprocesses upregulated under poor diet, overlapping with the study by Ament et al. (2011). Upregulation in healthy bees (no-nosema) under carbohydrates-only feeding is represented compared to pollen (C &gt; P), and in presence of Nosema compared to MegaBee (MN &gt; CN) and pollen (PN &gt; CN). Overlapping bioprocesses with the study by Ament et al. (2011) are listed; upregulated treatments in the latter study are forager vs. nurse vs. (F &gt; N), poor diet vs. rich (Pr &gt; R), vitellogenin RNAi vs. vitellogenin wild type (Vg(−) &gt; Vg). All listed bioprocesses are upregulated in this study (+); the non-concordant bioprocesses in direction of regulation in Ament et al. are indicated by the sign minus (−). (XLSX 11 kb)
DOI: 10.6084/m9.figshare.6999728
title: Additional file 6: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S6. Bioprocesses upregulated under rich diet overlapping with the study by Ament et al. (2011). In the present study, upregulation in healthy bees under Bee-Pro (B &gt; C), MegaBee (M &gt; C) and pollen (P &gt; C) feeding is represented compared to carbohydrates-only diet; respectively, BN &gt; CN, MN &gt; CN and PN &gt; CN represent the same diets comparisons in Nosema-infected bees. Overlapping bioprocesses with the study by Ament et al. (2011) are listed; upregulated treatments in the latter study are nurse vs. forager (N &gt; F), rich diet vs. poor (R &gt; Pr), vitellogenin wild type vs. vitellogenin RNAi (Vg &gt; Vg(−)), and queen mandibular pheromone treatment (QMP) vs. control (Q &gt; Ct). All listed bioprocesses are upregulated in this study (+); bioprocesses that are expressed in the opposite direction in Ament et al. are indicated with the sign minus (−). (XLSX 10 kb)
DOI: 10.6084/m9.figshare.6999728.v1
title: Additional file 6: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S6. Bioprocesses upregulated under rich diet overlapping with the study by Ament et al. (2011). In the present study, upregulation in healthy bees under Bee-Pro (B &gt; C), MegaBee (M &gt; C) and pollen (P &gt; C) feeding is represented compared to carbohydrates-only diet; respectively, BN &gt; CN, MN &gt; CN and PN &gt; CN represent the same diets comparisons in Nosema-infected bees. Overlapping bioprocesses with the study by Ament et al. (2011) are listed; upregulated treatments in the latter study are nurse vs. forager (N &gt; F), rich diet vs. poor (R &gt; Pr), vitellogenin wild type vs. vitellogenin RNAi (Vg &gt; Vg(−)), and queen mandibular pheromone treatment (QMP) vs. control (Q &gt; Ct). All listed bioprocesses are upregulated in this study (+); bioprocesses that are expressed in the opposite direction in Ament et al. are indicated with the sign minus (−). (XLSX 10 kb)
DOI: 10.6084/m9.figshare.6999716
title: Additional file 5: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S5. Bioprocesses and pathways upregulated in Nosema-infected bees under poor diet. Upregulated bioprocesses (GO-terms) and Kegg pathways in Nosema-infected bees under poor diet feeding (carbohydrates-only) compared to pollen (C &gt; P), Bee-Pro (C &gt; B) and MegaBee (CN &gt; MN). (XLSX 92 kb)
DOI: 10.6084/m9.figshare.6999716.v1
title: Additional file 5: of Transcriptional response of honey bee (Apis mellifera) to differential nutritional status and Nosema infection

description: Table S5. Bioprocesses and pathways upregulated in Nosema-infected bees under poor diet. Upregulated bioprocesses (GO-terms) and Kegg pathways in Nosema-infected bees under poor diet feeding (carbohydrates-only) compared to pollen (C &gt; P), Bee-Pro (C &gt; B) and MegaBee (CN &gt; MN). (XLSX 92 kb)